67% five-year survival rate in glioblastoma therapy, according to CANbridge Pharmaceuticals study
CANbridge Pharmaceuticals Inc. has announced that its therapy for glioblastoma has shown a 67% survival…
March 17, 2023 - 3 minutes
CANbridge Pharmaceuticals Inc. has announced that its therapy for glioblastoma has shown a 67% survival…
Enterome has completed patient enrollment in its phase 2 clinical trial (ROSALIE) evaluating its lead…
Northwest Biotherapeutics, which is developing DCVax personalized immune therapies for solid tumor cancers, yesterday (November…
A clinical stage drug company developing sulforaphane-based medicines for cancer treatment has started recruiting for…
A treatment for one of the most aggressive and difficult to treat cancers is the…